Research graph
References from Quarterly SHR-1918. Local targets link to admitted publications; unresolved targets remain external evidence.
Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease
10.1056/nejmoa1612790 · 2017 · External reference
Evinacumab for homozygous familial hypercholesterolemia
10.1056/nejmoa2004215 · 2020 · External reference
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia
10.1056/nejmoa2404147 · 2024 · External reference
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial
10.1016/s2213-8587(25)00290-6 · 2026 · External reference
Angiopoietin-like 3 antibody therapy in patients with suboptimally controlled hyperlipidemia: a phase 2 study
10.1016/j.jacc.2025.03.008 · 2025 · External reference
Efficacy and safety of quarterly dosing SHR-1918 in patients with suboptimally controlled hyperlipidemia
2026 · External reference
Anti-ANGPTL3 antibody SHR-1918 for homozygous familial hypercholesterolemia: a nonrandomized clinical trial
10.1001/jamacardio.2025.4878 · 2026 · External reference
Evolocumab and clinical outcomes in patients with cardiovascular disease
10.1056/nejmoa1615664 · 2017 · External reference
Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease
10.1001/jama.2018.20045 · 2019 · External reference
Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial
10.1093/eurjpc/zwae090 · 2024 · External reference
